

Electronic Supplementary Material

Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-month Follow-up Study

Xiaoyong Zhang^{1,4} • Suwen Lu¹ • Hui Li¹ • Yi Wang² • Zhen Lu² • Zhihong Liu¹ • Qingtao Lai¹ • Yali Ji¹ • Xuan Huang¹ • Yongyin Li¹ • Jian Sun¹ • Yingsong Wu³ • Xiaoning Xu⁵ • Jinlin Hou^{1,4}✉

1. State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510000, China

2. Department of Laboratory Medicine, The People's Hospital of Honghu, Jingzhou 433200, China

3. Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510000, China

4. Hepatology Unit, Shenzhen Hospital, Southern Medical University, Shenzhen 518000, China

5. Centre for Immunology and Vaccinology, Chelsea & Westminster Hospital, Faculty of Medicine, Imperial College, London W6, UK

Supporting information to DOI: 10.1007/s12250-020-00329-9

Table S1. Detection of IgM and IgG antibodies against SARS-CoV-2 NP at different time intervals.

Days after symptom onset	IgM+	IgG+	IgM+ or/and IgG+	No.
0–7	19 (73.08%)	15 (57.69%)	19 (73.08%)	26
8–14	32 (86.49%)	32 (86.49%)	34 (91.89%)	37
15–21	32 (72.73%)	35 (79.55%)	38 (86.36%)	44
22–28	51 (72.86%)	59 (84.29%)	65 (92.86%)	70
29–35	22 (56.41%)	38 (97.44%)	39 (100.00%)	39
36–42	19 (47.50%)	40 (100.00%)	40 (100.00%)	40
43–49	24 (44.44%)	54 (100.00%)	54 (100.00%)	54
50–56	17 (35.42%)	48 (100.00%)	48 (100.00%)	48
57–63	14 (43.75%)	32 (100.00%)	32 (100.00%)	32
64–70	5 (26.32%)	19 (100.00%)	19 (100.00%)	19
>70	1 (12.50%)	8 (100.00%)	8 (100.00%)	8

Note: Data are presented as n (%); NP, nuclecapsid protein.




Fig. S1: Relationship between persistence of SARS-CoV-2 RNA and antibody levels. P values and r values were derived from Spearman test.




Fig. S2. Temporal profile of total antibodies against SARS-CoV-2 NP measured by CIMA.